Kcentra approved to stop severe bleeding in heart patients

(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and similar products.

is the only other product approved for this use, the FDA said in a news release, but plasma requires blood typing and may require thawing. This means Kcentra usually can be administered more quickly than plasma to stop major bleeding.

Warfarin and similar anticoagulants are typically prescribed in cases of atrial fibrillation () and for people with an artificial heart valve, the FDA said.

Kcentra will carry a boxed label warning that it may increase users' risk of blood clots. Made from the pooled plasma of screened donors, it's processed to minimize recipients' risk of acquiring viruses and other germs, the agency said.

In a study of 216 people who had been receiving and who developed major bleeding, Kcentra was found to be as effective as plasma in treating the problem, the FDA said.

The drug is produced by the German company CSL Behring.

More information: To learn more about this approval, visit the FDA.

add to favorites email to friend print save as pdf

Related Stories

Varizig approved to reduce chickenpox symptoms

Dec 22, 2012

(HealthDay)—Varizig (varicella zoster immune globulin) has been approved by the U.S. Food and Drug Administration to minimize chickenpox symptoms when administered within four days of exposure to the virus ...

Octaplas approved for blood-clotting disorders

Jan 17, 2013

(HealthDay)—Octaplas has been approved by the U.S. Food and Drug Administration to augment insufficient clotting proteins that could otherwise lead to excessive bleeding or excessive clotting.

Recommended for you

Expression of privilege in vaccine refusal

3 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments